July 20, 2018 10:52 AM EDTUpdated 12:23 PM
Peer Review

An­tho­ny Quinn ce­ments Ae­glea CEO spot; Hu­man Longevi­ty bumps David Karow up to the top

Amber Tong

→ Af­ter prov­ing him­self in one year as in­ter­im CEO at Ae­glea Bio­Ther­a­peu­tics $AGLE, An­tho­ny Quinn is of­fi­cial­ly tak­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­clu­sive: Bain-backed mus­cu­loskele­tal biotech rais­es $120M for trio of clin­i­cal-stage bi­o­log­ics

The End­points 100: The biotech in­dus­try braces for Trump 2.0

Lil­ly’s oral SERD makes strides in breast can­cer with Phase 3 da­ta

Chro­ma, Nvel­op merge to form nChro­ma Bio, rais­ing $75M to en­ter the clin­ic

Q32 Bio’s stock crash­es af­ter atopic der­mati­tis fail, alope­cia tri­al sna­fu

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times